AssetMark Inc
CPRX

AssetMark Inc’s Catalyst Pharmaceutical CPRX Stock Holding History

AssetMark Inc’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.54M Buy
102,436
+16,299
+19% +$388K 0.01% 827
2025
Q4 		$2.01M Sell
86,137
-3,172
-4% -$70.7K ﹤0.01% 852
2025
Q3 		$1.76M Buy
89,309
+12,669
+17% +$261K ﹤0.01% 851
2025
Q2 		$1.66M Sell
76,640
-6,596
-8% -$156K ﹤0.01% 807
2025
Q1 		$2.02M Buy
83,236
+12,434
+18% +$280K 0.01% 721
2024
Q4 		$1.48M Sell
70,802
-1,443
-2% -$31K ﹤0.01% 775
2024
Q3 		$1.44M Buy
72,245
+1,704
+2% +$31.6K ﹤0.01% 718
2024
Q2 		$1.09M Buy
70,541
+1,866
+3% +$29.1K ﹤0.01% 743
2024
Q1 		$1.09M Buy
68,675
+3,997
+6% +$60.2K ﹤0.01% 713
2023
Q4 		$1.09M Buy
64,678
+2,505
+4% +$34.2K ﹤0.01% 660
2023
Q3 		$727K Buy
62,173
+6,218
+11% +$83.2K ﹤0.01% 685
2023
Q2 		$752K Sell
55,955
-2,093
-4% -$30.1K ﹤0.01% 654
2023
Q1 		$962K Buy
58,048
+566
+1% +$9.34K ﹤0.01% 606
2022
Q4 		$1.07M Sell
57,482
-1,650
-3% -$25.4K ﹤0.01% 555
2022
Q3 		$759K Buy
+59,132
New +$701K ﹤0.01% 578

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AssetMark Inc's CPRX Position: Q1 2026 in Review

AssetMark Inc increased its Catalyst Pharmaceutical (CPRX) stake by 19% in Q1 2026, buying an estimated $388K and bringing the position to 102,436 shares worth $2.54M. The position accounts for 0.01% of the portfolio, ranked #827.

AssetMark Inc first reported a position in CPRX in Q3 2022 and has held it in 15 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • AssetMark Inc held 102,436 shares of Catalyst Pharmaceutical worth $2.54M as of Q1 2026.
  • AssetMark Inc bought 16,299 Catalyst Pharmaceutical shares in Q1 2026, an estimated $388K.
  • Catalyst Pharmaceutical made up 0.01% of AssetMark Inc's portfolio in Q1 2026, its #827 holding.
  • AssetMark Inc first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 15 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.